

Docket No.: 246515US0DIV

OBLON
SPIVAK
MCCLELLAND
MAIER
A
NEUSTADT
P.C.

ATTORNEYS AT LAW

COMMISSIONER FOR PATENTS ALEXANDRIA, VIRGINIA 22313

RE: Application Serial No.: 10/749,387

Applicants: Naoyuki FUKUCHI, et al.

Filing Date: January 2, 2004

For: PROTEIN HAVING ANTITHROMBOTIC ACTIVITY

AND METHOD FOR PRODUCING THE SAME

Group Art Unit: 1653 Examiner: Liu, S.W.

SIR:

Attached hereto for filing are the following papers:

Response to Restriction Requirement

Our check in the amount of \$0.00 is attached covering any required fees. In the event any variance exists between the amount enclosed and the Patent Office charges for filing the above-noted documents, including any fees required under 37 C.F.R 1.136 for any necessary Extension of Time to make the filing of the attached documents timely, please charge or credit the difference to our Deposit Account No. 15-0030. Further, if these papers are not considered timely filed, then a petition is hereby made under 37 C.F.R. 1.136 for the necessary extension of time. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Stephen G. Baxter

Registration No. 32,884

Customer Number 22850

(703) 413-3000 (phone) (703) 413-2220 (fax) Vincent K. Shier, Ph.D. Registration No. 50,552

DOCKET NO.: 246515US0DIV

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

TN RE APPLICATION OF:

:

Naoyuki Fukuchi, et al.

: GROUP ART UNIT: 1653

SERIAL NO.: 10/749,387

:

FILED: JANUARY 2, 2004

: EXAMINER: LIU, S.W.

FOR: PROTEIN HAVING ANTITHROMBOTIC ACTIVITY AND METHOD FOR

PRODUCING THE SAME

RESPONSE TO RESTRICTION REQUIREMENT

COMMISSIONER FOR PATENTS ALEXANDRIA, VA 22313-1450

SIR:

Responsive to the Official Action dated March 25, 2005, Applicants elect, with traverse, Group I, Claims 1-11, for further prosecution.

REMARKS

The Office has required restriction in the present application as follows:

Group I:

Claims 1-11, drawn to a method of producing a protein;

Group II:

Claims 21-23, drawn to an isolated polynucleotide encoding the protein,

and a process of producing the protein comprising culturing a cell

transformed with said polynucleotide;

Group III:

Claims 25-26, drawn to an isolated polynucleotide encoding the protein,

and a process of producing the protein comprising culturing a cell transformed with said polynucleotide, wherein the polynucleotide (additionally) is characterized by comprising mutations in the region of the protein (encoded by said polynucleotide): amino acid residues

47-111, or a substitution mutation in residue 81 (Cys \rightarrow Ala);

Group IV:

Claims 27-30, drawn to an isolated polynucleotide encoding the protein,

and a process of producing the protein comprising culturing a cell